Covid-19 roundup: EMA ups Pfiz­er, Mod­er­na vac­cine man­u­fac­tur­ing ca­pa­bil­i­ties amid short­age

As vac­cine short­ages have caused coun­tries to scram­ble, sup­ply chain short­ages and even law­suits, the EMA has ap­proved an in­crease man­u­fac­tur­ing at Eu­ro­pean fa­cil­i­ties for both Pfiz­er-BioN­Tech and Mod­er­na’s Covid-19 vac­cines.

An in­crease in batch size at Pfiz­er’s Pu­urs, Bel­gium plant was ap­proved, in an ef­fort to suc­cess­ful­ly and safe­ly ramp up pro­duc­tion to in­crease the num­ber of dos­es avail­able. BioN­Tech CEO Ugur Sahin told Bloomberg TV last month that Pfiz­er and BioN­Tech could in­crease man­u­fac­tur­ing ca­pac­i­ty to pro­duce 3 bil­lion dos­es next year, and could cre­ate 2 bil­lion by 2021’s end. CFO Sierk Po­et­ting has al­so said that con­struct­ing new pro­duc­tion sites to keep up with de­mand is pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER